肝脏 ›› 2023, Vol. 28 ›› Issue (11): 1323-1327.

• 肝癌 • 上一篇    下一篇

COMPASS-CAT、Khorana评分及D-D、FDP预测肝癌患者静脉血栓发生的价值观察

储庆云, 高艳, 刘艳, 李承慧   

  1. 246000 安徽 安庆市立医院肿瘤内科
  • 收稿日期:2023-04-02 出版日期:2023-11-30 发布日期:2024-03-03
  • 通讯作者: 李承慧

The value of COMPASS-CAT, Khorana score, D-dimer (D-D) and fibrin degradation products (FDP) in predicting venous thrombosis in patients with liver cancer

CHU Qing-yun, GAO Yan, LIU Yan, LI Cheng-hui   

  1. Department of Internal Medicine-Oncology,Anqing Municipal Hospita, Anhui 246000, China
  • Received:2023-04-02 Online:2023-11-30 Published:2024-03-03
  • Contact: LI Cheng-hui

摘要: 目的 研究COMPASS-CAT、Khorana评分及D-二聚体(D-D)、纤维蛋白降解产物(FDP)预测肝癌患者静脉血栓发生的价值。方法 回顾性分析2021年8月至2023年8月125例肝癌患者的临床资料,根据治疗后3 d内静脉血栓栓塞症(VTE)发生情况分为VTE组27例和非VTE组98例。比较两组患者的COMPASS-CAT和Khorana评分,检测两组血清D-D、FDP水平。ROC曲线分析血清D-D、FDP单独及联合COMPASS-CAT评分预测肝癌患者发生VTE的风险;多因素分析采取非条件logistic逐步回归分析。结果 VTE组有VTE史5例(18.52%)、高血压11例(40.74%)、中心静脉导管应用9例(33.33%)、COMPASS-CAT评分≥7分的患者19例(70.37%)、血清D-D水平为(21.04±7.81)mg/L、血清FDP水平为(62.55±20.48)μg/mL,均高于非VTE组的0例、7例(14.00%)、4例(8.00%)、15例(30.00%)、(6.65±2.19)mg/L、(17.96±5.82)μg/mL(P<0.05)。经ROC分析,血清D-D、FDP单独及联合预测肝癌患者发生VTE的曲线下面积分别为0.911(95%CI:0.842~0.980)、0.883(95%CI:0.792~0.973)、0.949(95%CI:0.900~0.998)。经多因素logistic回归分析,VTE史、高血压、中心静脉导管应用、COMPASS-CAT评分、血清D-D及FDP是肝癌患者发生VTE的危险因素(P<0.05)。结论 COMPASS-CAT评分、血清D-D及FDP可用于预测肝癌患者是否发生VTE,血清D-D、FDP和COMPASS-CAT评分联合可进一步提高预测价值。

关键词: 肝癌, 静脉血栓栓塞症, COMPASS-CAT评分, Khorana评分, D-二聚体, 纤维蛋白降解产物

Abstract: Objective To evaluate the value of COMPASS-CAT, Khorana score, D-dimer (D-D), and fibrin degradation products (FDP) in predicting venous thrombosis in patients diagnosed with liver cancer.Methods A retrospective analysis was conducted on the clinical data of 125 patients with liver cancer from August 2021 to August 2023. These patients were divided into two groups: the VTE group (27 cases) and the non-VTE group (98 cases) based on the occurrence of venous thromboembolism (VTE) within 3 days after treatment. The clinical data of all patients were collected, including their COMPASS-CAT and Khorana scores, as well as the levels of serum D-D and FDP 3 day after radical resection of liver cancer. The predictive value of serum D-D, FDP alone and in combination with COMPASS-CAT score in predicting the occurrence of VTE in patients with liver cancer was analyzed using ROC curve. Multivariate analysis was conducted using unconditional logistic stepwise regression analysis.Results The VTE group had 5 cases (18.52%) with a history of VTE, 11 cases (40.74%) with hypertension, 9 cases (33.33%) with a central venous catheter, 19 cases (70.37%) with a COMPASS CAT score ≥7, serum D-D level of (21.04±7.81) mg/L, and serum FDP level of (62. 55±20.48) μg/mL. These numbers were all higher compared to the non-VTE group, which had 0 cases with a VTE history (0.00%), 7 cases with hypertension (14.00%), 4 cases with a central venous catheter (8.00%), 15 cases with a COMPASS-CAT score ≥7 (30.00%), serum D-D level of (6.65±2.19) mg/L, and serum FDP level of (17.96±5.82) μg/mL (P<0.05). The area under the ROC curve of serum D-D and FDP, and their combination in predicting the occurrence of VTE in liver cancer patients was 0.911, 0.883, and 0.949, respectively. Multivariate logistic regression analysis showed that a history of VTE, hypertension, central venous catheter, COMPASS-CAT score, serum D-D and FDP were risk factors for VTE in patients with liver cancer (P<0.05).Conclusion COMPASS-CAT score, serum D-D and FDP show significant differences between VTE group and non-VTE group, and can be used to predict the occurrence of VTE in patients with liver cancer. However, the Khorana score does not show a significant difference between the two groups and has limited predictive value. In addition, combining the prediction of serum D-D, FDP and COMPASS-CAT score can further enhance the predictive value.

Key words: Liver cancer, Venous thromboembolism, COMPASS-CAT score, Khorana score, D-dimer, Fibrin degradation products